<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545584</url>
  </required_header>
  <id_info>
    <org_study_id>0431-078</org_study_id>
    <secondary_id>2007_023</secondary_id>
    <nct_id>NCT00545584</nct_id>
  </id_info>
  <brief_title>Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)</brief_title>
  <official_title>Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of three strategies of lifestyle changes associated with Januvia
      (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately
      controlled by metformin (hemoglobin A1c [HbA1c] 6.5-9%). A difference between the three
      strategies of lifestyle changes was expected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2007</start_date>
  <completion_date type="Actual">November 19, 2009</completion_date>
  <primary_completion_date type="Actual">November 19, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c Measurement</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Measurement</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Generally FPG values of ~5.0-7.2 mmol/L would be considered goal (American Diabetes Association).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1512</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Sitagliptin with Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin with Diet Advice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet which includes advice on diet with a leaflet and a diary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin with Diet and Physical Activity Advice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin phosphate</intervention_name>
    <description>sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks</description>
    <arm_group_label>Sitagliptin with Standard of Care</arm_group_label>
    <arm_group_label>Sitagliptin with Diet Advice</arm_group_label>
    <arm_group_label>Sitagliptin with Diet and Physical Activity Advice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Comparator: Diet</intervention_name>
    <description>Diet</description>
    <arm_group_label>Sitagliptin with Diet Advice</arm_group_label>
    <arm_group_label>Sitagliptin with Diet and Physical Activity Advice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Comparator: Physical Activity</intervention_name>
    <description>Physical Activity</description>
    <arm_group_label>Sitagliptin with Diet and Physical Activity Advice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged &gt;/= 18 years,with T2DM and treated with the maximal tolerated dose
             of metformin, with documented or high likely inadequate control of diabetes (HbA1c
             6.5-9%)

        Exclusion Criteria:

          -  Daily insulin treatment or one insulin dose or more within the last 8 weeks or
             expected insulin treatment within the next 3 months.

          -  Hypoglycemia unawareness or recurrent major hypoglycemia or history of acidoketosis

          -  Known hypersensitivity or contraindication to metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <results_first_submitted>April 19, 2011</results_first_submitted>
  <results_first_submitted_qc>April 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 11, 2011</results_first_posted>
  <disposition_first_submitted>November 18, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 17, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 8, 2011</disposition_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1512 subjects were selected/screened, 380 subjects failed screening, leaving 1132 subjects who were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin With Standard of Care</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
No specific intervention (standard recommendation) on physical exercise and diet.</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin With Diet Advice</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet which includes advice on diet with a leaflet and a diary</description>
        </group>
        <group group_id="P3">
          <title>Sitagliptin With Diet and Physical Activity Advice</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="412"/>
                <participants group_id="P2" count="414"/>
                <participants group_id="P3" count="306">306 subjects were randomized but only 305 were treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="334"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Only one reason for discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Two or more reasons for discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin With Standard of Care</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
No specific intervention (standard recommendation) on physical exercise and diet.</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin With Diet Advice</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet which includes advice on diet with a leaflet and a diary</description>
        </group>
        <group group_id="B3">
          <title>Sitagliptin With Diet and Physical Activity Advice</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="362"/>
            <count group_id="B2" value="358"/>
            <count group_id="B3" value="265"/>
            <count group_id="B4" value="985"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The Full Analysis Set (FAS) population included all selected patients with at least one measured HbA1c value after Visit 2 and having received at least one dose of sitagliptin.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.26" spread="10.04"/>
                    <measurement group_id="B2" value="57.47" spread="9.12"/>
                    <measurement group_id="B3" value="57.30" spread="9.90"/>
                    <measurement group_id="B4" value="57.71" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>The Full Analysis Set (FAS) population included all selected patients with at least one measured HbA1c value after Visit 2 and having received at least one dose of sitagliptin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="482"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1c Measurement</title>
        <description>Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The Full Analysis Set (FAS) population included all selected patients with at least one measured HbA1c value after Visit 2 and having received at least one dose of sitagliptin. In the Standard of Care group, only 360 subjects had HbA1c Baseline evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin With Standard of Care</title>
            <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
No specific intervention (standard recommendation) on physical exercise and diet.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin With Diet Advice</title>
            <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet which includes advice on diet with a leaflet and a diary</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin With Diet and Physical Activity Advice</title>
            <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c Measurement</title>
          <description>Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.</description>
          <population>The Full Analysis Set (FAS) population included all selected patients with at least one measured HbA1c value after Visit 2 and having received at least one dose of sitagliptin. In the Standard of Care group, only 360 subjects had HbA1c Baseline evaluations.</population>
          <units>percent HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=360, 358, and 265, respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.37" spread="0.61"/>
                    <measurement group_id="O2" value="7.50" spread="0.66"/>
                    <measurement group_id="O3" value="7.49" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=362, 358, and 265, respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="1.09"/>
                    <measurement group_id="O2" value="7.42" spread="1.15"/>
                    <measurement group_id="O3" value="7.40" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Measurement</title>
        <description>Generally FPG values of ~5.0–7.2 mmol/L would be considered goal (American Diabetes Association).</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS population. Furthermore, only 350, 252, and 350 subjects had FPG evaluations in the Diet advice, Diet &amp; physical activity advice, and Standard groups, respectively, at Baseline; and 303, 224, and 310 subjects had FPG evaluations in the Diet advice, Diet &amp; physical activity advice, and Standard groups, respectively, at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin With Standard of Care</title>
            <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
No specific intervention (standard recommendation) on physical exercise and diet.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin With Diet Advice</title>
            <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet which includes advice on diet with a leaflet and a diary</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin With Diet and Physical Activity Advice</title>
            <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Measurement</title>
          <description>Generally FPG values of ~5.0–7.2 mmol/L would be considered goal (American Diabetes Association).</description>
          <population>FAS population. Furthermore, only 350, 252, and 350 subjects had FPG evaluations in the Diet advice, Diet &amp; physical activity advice, and Standard groups, respectively, at Baseline; and 303, 224, and 310 subjects had FPG evaluations in the Diet advice, Diet &amp; physical activity advice, and Standard groups, respectively, at Week 24.</population>
          <units>mmol/L glucose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="303"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=350, 350, 252, respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.87" spread="1.98"/>
                    <measurement group_id="O2" value="9.00" spread="2.03"/>
                    <measurement group_id="O3" value="8.91" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=310, 303, and 224, respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.21" spread="2.07"/>
                    <measurement group_id="O2" value="8.32" spread="2.08"/>
                    <measurement group_id="O3" value="8.47" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This safety data includes AEs and SAEs that occurred during treatment (Visit 2 to Visit 4).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin With Standard of Care</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
No specific intervention (standard recommendation) on physical exercise and diet.</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin With Diet Advice</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet which includes advice on diet with a leaflet and a diary</description>
        </group>
        <group group_id="E3">
          <title>Sitagliptin With Diet and Physical Activity Advice</title>
          <description>Subjects received sitagliptin 100 mg once daily for 26 Weeks,
and:
Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="412"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="414"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IDIOPATHIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>ADAMS-STOKES SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>MACULAR OPACITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>DRUG EXPOSURE DURING PREGNANCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>LIMB TRAUMATIC AMPUTATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>FIBROMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CERVICAL ROOT PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>GENITAL PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="414"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="414"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

